H-Aggregated IR-1061 NIR-II Dye Enhances Cancer PTT and Imaging

Study Background and Research Question

Photothermal therapy (PTT) and near-infrared (NIR) fluorescence imaging have emerged as promising modalities for cancer diagnosis and treatment due to their minimally invasive nature and high tissue penetration. The second NIR window (NIR-II, 1000–1700 nm) offers superior imaging depth and spatial resolution compared to the NIR-I range, making it highly attractive for in vivo applications. However, most small-molecule NIR-II fluorophores struggle to balance strong fluorescence with effective photothermal conversion, limiting their potential for integrated diagnosis and therapy (Yu et al., 2023).

Yu et al. addressed the following research question: Can the aggregation state of an organic NIR-II fluorophore be manipulated to provide both robust fluorescence imaging and efficient photothermal therapy, while ensuring tumor-specific delivery and function in vivo?

Key Innovation from the Reference Study

The central innovation is the construction of a multifunctional liposomal nanosystem, RRIALP-C4, encapsulating the NIR-II fluorophore IR-1061 and the chemotherapeutic agent carboplatin. This system is uniquely coated with the RR9 peptide, granting it tumor-specific targeting via αvβ3 integrin recognition. Critically, the study leverages the H-aggregated state of IR-1061 within the liposome, which not only preserves but enhances both photothermal and fluorescence properties upon transfer to the tumor cell membrane through peptide-mediated fusion (Yu et al., 2023).

Methods and Experimental Design Insights

The authors used a rational design strategy informed by molecular dynamics simulations to promote H-aggregation of IR-1061 within the liposomal bilayer. The RRIALP-C4 system was prepared by loading IR-1061 and carboplatin into anionic liposomes, followed by surface functionalization with the RR9 peptide. Experimental protocols included:

• Molecular dynamics simulation to characterize IR-1061's aggregation and interactions with the lipid bilayer.
• Fluorescence and absorption spectroscopy to confirm H-aggregation and assess optical properties.
• In vitro evaluation of membrane fusion and transfer efficiency to tumor cells.
• In vivo imaging and therapy studies in tumor-bearing mice, assessing biodistribution, fluorescence imaging, and PTT efficacy.

Protocol Parameters

• aggregation state | H-aggregate (vs. monomeric) | enhances PTT & imaging | H-aggregation boosts photothermal conversion without compromising NIR-II fluorescence | paper
• fluorophore concentration | optimized at liposome:IR-1061 10:1 (mol/mol) | NIR-II FI and PTT | Ensures stable aggregation and signal | paper
• laser irradiation | 808 nm, 1.0 W/cm², 5 min | photothermal therapy | Standard for PTT with NIR dyes | paper
• solvent for IR-1061 prep | DMSO ≥25.65 mg/mL | stock solution prep | IR-1061 is insoluble in ethanol and water, requiring DMSO for dissolution | product_spec
• RR9 peptide density | 5–10 mol% of lipid | tumor targeting efficiency | Balances targeting with colloidal stability | workflow_recommendation

Core Findings and Why They Matter

Yu et al. demonstrated that H-aggregated IR-1061 in RRIALP-C4 maintains its optical and photothermal properties after transfer from the liposome to the tumor cell membrane, enabled by RR9-mediated membrane fusion. Key findings include:

• Dual-functionality: RRIALP-C4 offers both NIR-II fluorescence imaging and NIR-I triggered PTT, providing high tumor-to-background contrast and effective ablation of tumor tissue in vivo (paper).
• Synergistic Therapy: The system enables temperature-sensitive release of carboplatin, offering combined photothermal and chemotherapeutic effects for enhanced tumor suppression.
• Tumor-Specific Targeting: RR9 peptide functionalization ensures selective binding and fusion with αvβ3-positive tumor cells, improving delivery and minimizing off-target effects.
• High Signal-to-Background Ratio: In vivo imaging revealed clear delineation of tumor margins and vasculature, supporting real-time monitoring of therapeutic response.

These findings highlight the potential for molecular aggregation strategies to overcome intrinsic limitations of small-molecule NIR-II fluorophores, enabling integrated imaging and therapy without relying on rigidification or nanocarrier-induced structural changes that can compromise fluorescence (Yu et al., 2023).

Comparison with Existing Internal Articles

Several internal resources expand on the application and optimization of IR-1061 as a near infrared fluorescent dye for biomedical research. For example, the article "Polystyrene Nanoparticles Enhance IR-1061 NIR Imaging for Deep Tissue" discusses nanoparticle encapsulation techniques to improve the optical performance and stability of IR-1061, complementing Yu et al.'s lipid-based approach by offering alternative matrices for dye delivery and aggregation control. Similarly, "IR-1061: Near Infrared Fluorescent Dye for Deep Imaging" provides protocol optimizations and troubleshooting for in vivo imaging workflows, relevant for adapting RRIALP-C4-like systems to varied research settings.

Unlike these guides, which focus on formulation and application in imaging, Yu et al. directly address the challenge of maintaining synergistic photothermal and imaging functions through aggregation-state engineering and membrane targeting, representing a mechanistic advance in the field.

Limitations and Transferability

Despite its promise, the RRIALP-C4 system faces several translational challenges. The reliance on specific peptide-mediated targeting (RR9) and the need to maintain H-aggregation of the fluorophore may complicate scale-up and reproducibility in heterogeneous biological environments. Additionally, the safety and pharmacokinetics of repeated administration, as well as potential immunogenicity of the peptide, require further investigation before clinical translation (paper).

Transferability to other cancer models or imaging/therapy contexts will depend on the expression profile of the targeted integrin and the physicochemical stability of the nanosystem in vivo. Researchers are advised to validate aggregation states and targeting efficiency in their specific systems (workflow_recommendation).

Research Support Resources

For researchers aiming to replicate or extend these findings, high-purity near infrared fluorescent dyes are essential. IR-1061 (SKU C8242) from APExBIO is a well-characterized NIR dye, suitable for in vivo optical imaging and compatible with DMSO-based formulations. Its solubility, spectral properties, and batch-tested purity support advanced biomedical research workflows. For optimal performance, prepare solutions fresh, avoid ethanol or water as solvents, and store as recommended. This product can be integrated into lipid or polymer nanocarriers following protocols outlined here and in related workflow guides (repirinastkits.com).